A sponsored-style look at compounded tirzepatide and semaglutide through telehealth firm Mochi Health, noting compounded drugs aren't FDA approved for safety or quality.
Recap by typeshit. Full story at The Detroit News.
A general explainer on how GLP-1 receptor agonists affect blood sugar and appetite, with advice on support while taking them.
Among the items: Walmart plans free GLP-1 diabetes drugs for employees in 2027, and Verdiva Bio dropped a phase II oral GLP-1 study citing market changes.
Longevity Technology reports BodySpec's new offering targets GLP-1 users worried about muscle, with body scans said to take about 12 minutes.
3:21
A short upload with no description, so the reasoning behind the claim isn't given. Worth a tap only if you follow the gray market retatrutide talk.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Alicia Butterfield claims Anthem denied her Zepbound once the drug got her below morbid obesity. A Los Angeles judge stayed her case pending arbitration.
Loading…